Compare ALTO & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTO | OCGN |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.7M | 419.8M |
| IPO Year | 2005 | 2014 |
| Metric | ALTO | OCGN |
|---|---|---|
| Price | $4.99 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 2.5M | ★ 6.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | 31.58 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $917,927,000.00 | N/A |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $0.43 | $1,718.38 |
| P/E Ratio | $102.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $0.90 |
| 52 Week High | $6.00 | $2.73 |
| Indicator | ALTO | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 58.60 |
| Support Level | $4.27 | $1.38 |
| Resistance Level | $5.07 | $1.58 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 13.04 | 91.94 |
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").